General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Immuneering in Series A Financing

December 16, 2019
The US$17 Million financing was led by a Boston-based emerging company team.

Immuneering Corporation has announced the completion of a US$17 million Series A financing. The financing was led by Boxcar PMJ LLC. Concurrent with the financing, Boxcar’s founding partner Joseph Kekst will join Immuneering’s board of directors and Boxcar’s founding partner Peter Feinberg will join as an observer. Immuneering plans to use the proceeds from the financing to advance its lead program in cancer cachexia and its pipeline of oncology medicines driven by its Disease Cancelling Technology (DCT). The company will also use proceeds to further develop its technology platforms, launch new drug programs in other disease areas and support the growth of its computational biology services business.

Latham & Watkins LLP represents Immuneering Corporation in the transaction with a Boston-based emerging companies team led by partners John Chory and Evan Smith with associate Andres Caicedo.